(NASDAQ: GTBP) Gt Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.18%.
Gt Biopharma's earnings in 2026 is -$58,423,000.On average, 3 Wall Street analysts forecast GTBP's earnings for 2026 to be -$12,506,615, with the lowest GTBP earnings forecast at -$12,016,160, and the highest GTBP earnings forecast at -$12,874,457. On average, 3 Wall Street analysts forecast GTBP's earnings for 2027 to be -$9,931,724, with the lowest GTBP earnings forecast at -$9,542,244, and the highest GTBP earnings forecast at -$10,223,833.
In 2028, GTBP is forecast to generate -$8,092,516 in earnings, with the lowest earnings forecast at -$7,775,162 and the highest earnings forecast at -$8,330,531.